New Health Sciences
Lexington
About New Health Sciences
New Health Sciences is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods potentially extending the shelf life of refrigerated red blood cells while improving their quality across the storage cycle. NHSi has financed development of the Hemanext technology through private investor funding and a series of NIH SBIR grants.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $51.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2021)
- Website: newhealthsciences.com
- Phone: 3014934360
Industries & Categories
Biopharma, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/new-health-sciences-70653 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.